Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Oxford Finance
AddedFeb 13, 2024
UpdatedJun 28, 2026
Oxford Finance

Oxford Finance

Operating

Oxford Finance LLC: Global provider of financial solutions, specializing in healthcare and life sciences sectors.

Location
Alexandria, VA, US
Founded
2002
Firm
Compare
Portfolio
Employees
Website

Investments

Headspace
Headspace

Total Raised

$320.9M

Rounds

13

Debt Financing$105MJuly 2023
Amino
Amino

Total Raised

$125.1M

Rounds

9

Debt Financing$42MMay 2023
Pearl Street Dental Partners
Pearl Street Dental Partners

Total Raised

$115M

Rounds

1

Debt Financing$115MNovember 2022
Renibus Therapeutics
Renibus Therapeutics

Total Raised

$214.7M

Rounds

8

Debt Financing$10MNovember 2022
Antheia
Antheia

Total Raised

$135.1M

Rounds

7

Debt Financing$40MJune 2022
Selux Diagnostics
Selux Diagnostics

Total Raised

$172.5M

Rounds

9

Debt Financing$30MJune 2022
Verastem
Verastem
Public

Total Raised

$280M

Rounds

9

Public$25MMarch 2022
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Public

Total Raised

$563.6M

Rounds

11

Post Ipo Debt$150MMarch 2022
Choice Health at Home
Choice Health at Home

Total Raised

$190M

Rounds

2

Debt Financing$190MJanuary 2022
Kezar Life Sciences
Kezar Life Sciences
Public

Total Raised

$123M

Rounds

5

Post Ipo Debt$50MNovember 2021
Viracta Therapeutics
Viracta Therapeutics
Public

Total Raised

$194.9M

Rounds

11

Post Ipo Debt$50MNovember 2021
Platelet BioGenesis
Platelet BioGenesis

Total Raised

$132.1M

Rounds

14

Series B$75.5MNovember 2021
Nature's Fynd
Nature's Fynd

Total Raised

$509.6M

Rounds

6

Debt Financing$45MDecember 2020
RxSight
RxSight
Public

Total Raised

$236M

Rounds

10

Debt Financing$60MDecember 2020
Vedanta Biosciences
Vedanta Biosciences

Total Raised

$433.1M

Rounds

15

Debt Financing$15MSeptember 2020
Enable Injections
Enable Injections

Total Raised

$347M

Rounds

8

Debt Financing$25MSeptember 2020
Selecta Biosciences
Selecta Biosciences
Public

Total Raised

$380.5M

Rounds

21

Public$35MSeptember 2020
Epic Healthcare Staffing
Epic Healthcare Staffing

Total Raised

$104.3M

Rounds

1

Debt Financing$104.3MMarch 2020
Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Debt Financing$60MFebruary 2020
Genapsys
Genapsys
Acquired

Total Raised

$319M

Rounds

9

Debt$75MFebruary 2020
Equillium
Equillium
Public

Total Raised

$85M

Rounds

5

Post Ipo Debt$20MOctober 2019
Xeris Biopharma Holdings
Xeris Biopharma Holdings
Public

Total Raised

$289.7M

Rounds

14

Post Ipo Debt$85MSeptember 2019
Talphera
Talphera
Public

Total Raised

$191.7M

Rounds

13

Post Ipo Debt$25MJune 2019
RefleXion Medical
RefleXion Medical

Total Raised

$675.1M

Rounds

11

Debt Financing$60MMay 2019
Summit Healthcare Reit
Summit Healthcare Reit

Total Raised

$96M

Rounds

1

Debt Financing$96MApril 2019